Personalized 6-Month Program to Reduce Frailty in Older Adults Undergoing Surgery for Bladder or Kidney Cancer
Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2025-12-09
106
Participants Needed
2
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Bladder and kidney cancers are often diagnosed in older adults, and surgery is the main treatment for these patients. Older individuals frequently face challenges such as fatigue, reduced fitness, muscle loss, pain from disease or treatment, and poor nutrition, which increase the risk of complications and frailty after surgery. Researchers are evaluating a personalized 6-month program designed to reduce frailty in older patients undergoing surgery for bladder or kidney cancer.
The study compares two groups a control group receiving standard care, which includes assessment by an oncogeriatrician followed by surgery and rehabilitation, and an interventional group receiving standard care plus a customized program. This program involves two adapted physical activity sessions per week for four weeks before and after surgery, therapeutic education workshops addressing physical activity, nutrition, treatments, fatigue, and relaxation, and a referral to a 12-week bridge program with weekly physical activity sessions.
Participants will be monitored through questionnaires and physical assessments at baseline, and at 1, 2, 3, and 6 months. Researchers will measure frailty, illness burden, physical activity levels, nutrition, memory, quality of life, fatigue, depression, muscle strength, and balance. The study includes safety follow-up and aims to evaluate patient frailty from day 1 to month 6 after surgery, with total participation lasting six months.
CONDITIONS
Brief Title
Effectiveness of a Personalized 6-month Programme on Frailty in Older Patients Treated for Bladder or Kidney Cancer.
Research Team
E
Evolène FAYOLLE, student
A
Amandine BAUDOT, Project Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
No severe cognitive impairment preventing understanding of the protocol
Affiliated or entitled to a social security scheme
Provided informed consent to participate in the study
You will not qualify if you...
Surgery already done
Significant co-morbidities contraindicating physical activity such as cardiac, respiratory, or disabling joint conditions
Deprived of liberty or under guardianship
Currently receiving prehabilitation with a private physiotherapist
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Run-in Period
Duration - 4 weeks
Participants in the interventional group attend 2 adapted physical activity (APA) sessions per week for 4 weeks before surgery.
2 sessions per week
Treatment
Duration - 6 months
Participants undergo surgery followed by a personalized 6-month care pathway including 2 APA sessions per week for 4 weeks post-surgery, therapeutic education workshops tailored to individual needs, and a 12-week bridge program with one APA session per week.
2 APA sessions per week for 4 weeks post-surgery, therapeutic education workshops as scheduled, and 1 APA session per week for 12 weeks during the bridge program
Follow-up
Duration - 6 months
Participants complete follow-up assessments including questionnaires and physical assessments at baseline, 1, 2, 3, and 6 months.
Visits at baseline, 1, 2, 3, and 6 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase 1 Study Evaluating Safety and Pharmacokinetics of Intravesical UGN-501 in Adults with Recurrent Non-Muscle Invasive Bladder Cancer
Predicting Recurrence and Progression Risk After Bladder Tumor Surgery Using Intraoperative Fluid Absorption and Blood DNA Changes
Evaluation of T-bren Versus Platinum-Based Chemotherapy for HER2-Expressing Metastatic Urothelial Cancer After Anti-PD-L1 Therapy Progression
Phase 2 Study of Gemcitabine Chemoablation for Treating Low-Grade Bladder Cancer
Single Arm, Open-Label Trial Evaluating Safety and Effectiveness
Study of Vitamin B3 with Tislelizumab, Gemcitabine, and Cisplatin for Bladder Cancer Patients
Evaluating Safety and Effects Following Antibiotic Use
Virtual Exercise Program to Maintain Function and Prevent Disability in Cancer Patients Undergoing Chemotherapy
Phase 3 Study of Disitamab Vedotin Combined with BCG Versus BCG Alone in Adults with HER2-Positive, High-Risk Non-Muscle-Invasive Bladder Cancer
Personalized 6-Month Program to Reduce Frailty in Older Adults Undergoing Surgery for Bladder or Kidney Cancer
Phase 3 Randomized Trial Comparing Intravesical TARA-002 to Chemotherapy in Adults With BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer
Randomized Study Comparing Active Surveillance to Continued Systemic Immunotherapy After Tumor-Free Status in Extensive Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effectiveness of a personalised 6-month programme on physical frailty in older patients treated for bladder or kidney cancer - FRAGECO program - multicenter, controlled, randomized study protocol.